TRIM21 and interstitial lung disease: Further studies are required to support the hypothesis of increased risk of lung fibrosis and PPF in anti-Ro52 positive patients with idiopathic inflammatory myopathies myositis-ILD, and to elucidate the possible role of Ro52/TRIM21 in the pathogenesis of lung fibrosis.